| | | | |
CUSIP No. 77634L 105 | | Schedule 13D | | Page 11 of 14 |
This Amendment No. 8 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on July 1, 2022, as amended on October 3, 2023, February 7, 2024, February 26, 2024, April 29, 2024, May 7, 2024, June 14, 2024 and July 1, 2024 (collectively, the “Original Schedule 13D” and, as amended and supplemented by this Amendment, this “Statement”), with respect to the Common Stock. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.
Item 4. Purpose of Transaction.
Item 4 of the Original Schedule 13D is amended and supplemented by adding the following:
On July 1, 2024, the Investors submitted the July 1 Waiver Request to the Issuer, and the Issuer promptly approved the submission by the Investors or their affiliates of confidential private acquisition proposals to the Issuer and compliance with associated disclosure requirements. On July 2, 2024, New Mountain Capital L.L.C., on behalf of certain managed funds, delivered to the Special Committee (the “Special Committee”) of the Board of Directors of the Issuer (the “Board”) a non-binding proposal (the “Proposal”) to acquire all of the outstanding shares of the Issuer’s Common Stock not owned by the Investors for a purchase price of $13.25 per share in cash (the “Proposed Transaction”).
No response has been provided to the Proposal. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee and the Board, stockholder approval and approval by (or clearance from) any applicable regulatory authorities. No assurances can be given that a definitive agreement will be reached, that the Proposed Transaction will be consummated, or that the Proposed Transaction will be consummated on the terms set forth in the Proposal. While the Proposal and the Proposed Transaction remain under consideration by the Issuer, the Reporting Persons and their affiliates expect to respond to inquiries from, and, if invited, to negotiate the terms of the Proposal with, the Issuer and its representatives. The Reporting Persons do not intend to provide additional disclosure regarding the Proposal or the Proposed Transaction unless and until a definitive agreement has been reached, or unless disclosure is otherwise required under applicable U.S. securities laws.
The Reporting Persons and their affiliates reserve the right to modify the Proposal at any time. Subject to the restrictions set forth in the Investor Rights Agreement, the Reporting Persons and their affiliates reserve the right to formulate other plans or make other proposals which could result in one or more of the transactions, events or actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, and to modify or withdraw any such plan or proposal at any time. Subject to the restrictions set forth in the Investor Rights Agreement, if the Proposed Transaction is not consummated, the Reporting Persons and their affiliates will continue to regularly review and assess their investment in the Issuer and, depending on market conditions and other factors, may determine, from time to time, to engage in any of the events set forth in clauses (a) through (j) of Item 4 of Schedule 13D.
The foregoing description of the Proposal does not purport to be complete and is subject to, and qualified in its entirety by, reference to the full text of the Proposal, which is attached hereto as Exhibit 9.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Original Schedule 13D is amended and restated in its entirety as follows:
The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Statement and the information set forth or incorporated in Items 2, 3, 4 and 6 is incorporated by reference in its entirety into this Item 5.
(a) and (b) The percentages in this Item 5 and in other provisions of this Statement relating to beneficial ownership of Common Stock are based on based on 421,255,230 shares of Common Stock outstanding as of May 8, 2024, as reported by the Issuer in the Form 10-Q.
(c) None of the Reporting Persons has effected any transaction in the shares of Common Stock during the past 60 days.